Journal Home
Access this journal onSciVerse ScienceDirect
Visit SciVerse ScienceDirect to see if you have access via your institution.
Search for

Volume 3, Issue 7, Page 5 (July 2008)


View previous. 6 of 52 View next.

ADVANCE, ACCORD: No Cardiovascular Benefit

SHERRY BOSCHERT (San Francisco Bureau)

SAN FRANCISCO — Lowering hemoglobin A1c levels below currently recommended levels did not reduce the risk of macrovascular events in high-risk patients with established type 2 diabetes in two large studies, and significantly increased the risk of death in one of the studies.

PII: S1558-0164(08)70246-3

doi:10.1016/S1558-0164(08)70246-3


View previous. 6 of 52 View next.